BioRestorative Therapies, Inc. Share Price Other OTC
Stocks
BRTX
US0906554086
Biotechnology & Medical Research
| Market Cap | 7.39M 6.5M 6.05M 5.55M 10.43M 709M 10.56M 71.87M 28.07M 350M 27.74M 27.14M 1.21B | P/E 2026 * |
-0.59x | P/E 2027 * | -0.72x |
|---|---|---|---|---|---|
| Enterprise Value | 7.39M 6.5M 6.05M 5.55M 10.43M 709M 10.56M 71.87M 28.07M 350M 27.74M 27.14M 1.21B | EV / Sales 2026 * |
5.26x | EV / Sales 2027 * | 3.2x |
| Free-Float |
87.87% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioRestorative Therapies, Inc.
| 1 day | +1.08% |
| Manager | Title | Age | Since |
|---|---|---|---|
Lance Alstodt
CEO | Chief Executive Officer | 55 | 15/11/2020 |
Robert Kristal
DFI | Director of Finance/CFO | 59 | 03/11/2021 |
Rory Rumore
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Lance Alstodt
CHM | Chairman | 55 | 15/11/2020 |
David Rosa
BRD | Director/Board Member | 61 | 28/10/2021 |
Mika Grasso
BRD | Director/Board Member | 28 | 11/06/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.08% | +0.25% | - | - | 7.39M | |
| -1.82% | +4.80% | +54.32% | +68.36% | 57.28B | |
| -0.27% | +5.74% | +40.26% | +80.17% | 54.99B | |
| -0.92% | -0.91% | +4.22% | +419.83% | 23.18B | |
| +2.88% | -0.36% | -18.58% | -12.54% | 22.59B | |
| -1.13% | +4.54% | +22.73% | -8.06% | 20.46B | |
| +1.57% | +3.30% | +27.41% | -29.07% | 17.56B | |
| -0.10% | +5.57% | +38.63% | +565.16% | 15.67B | |
| +5.29% | 0.00% | +185.09% | +332.66% | 14.46B | |
| +1.43% | +0.97% | +26.31% | +186.07% | 13.92B | |
| Average | +0.79% | +1.62% | +42.27% | +178.06% | 26.68B | |
| Weighted average by Cap. | +0.09% | +1.93% | +39.97% | +138.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.4M 1.24M 1.15M 1.06M 1.98M 135M 2.01M 13.67M 5.34M 66.53M 5.27M 5.16M 230M | 2.31M 2.03M 1.89M 1.74M 3.26M 222M 3.31M 22.49M 8.79M 110M 8.68M 8.49M 378M |
| Net income | -13.52M -11.89M -11.07M -10.16M -19.08M -1.3B -19.34M -132M -51.38M -640M -50.77M -49.67M -2.21B | -15.56M -13.68M -12.73M -11.69M -21.96M -1.49B -22.25M -151M -59.11M -737M -58.41M -57.15M -2.55B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
